Table 2.
Bivariate association with self-perception of assisting with future injection drug use initiation among who have provided previous injection drug initiation assistance by site (PRIMER; n = 865), n (%)
| Tijuana, Mexico (n = 73) | San Diego, USA (n = 86) | Vancouver, Canada (n = 707) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Would Initiate (n = 24) | Would not initiate (n = 49) | P | Would Initiate (n = 14) | Would not initiate (n = 72) | P | Would Initiate (n = 125) | Would not initiate (n = 582) | P | |
| Age, years, mean (SD) | 40.9 (9.5) | 38.3 (11.2) | 0.50 | 50.1 (14.1) | 43.6 (12.1) | 0.09 | 40 (13) | 43.9 (12.9) | <0.01 |
| Sex | |||||||||
| Men | 18 (36.7) | 31 (63.3) | 0.43 | 11 (18.6) | 48 (81.4) | 0.85 | 94 (20.3) | 370 (79.7) | 0.02 |
| Women | 6 (25.0) | 18 (75.0) | 3 (13.0) | 20 (87.0) | 31 (12.5) | 210 (87.5) | |||
| Transgender | - | - | 0 (0) | 3 (100) | - | - | |||
| Drug injection frequency, last 6 months | |||||||||
| None | 1 (20.0) | 4 (80.0) | >0.99 | 2 (6.3) | 30 (93.7) | <0.05 | 19 (8.1) | 216 (91.9) | <0.001 |
| Less than daily | 1 (33.3) | 2 (66.7) | 9 (30.0) | 21 (70.0) | 41 (18.9) | 176 (81.1) | |||
| Daily | 22 (33.9) | 43 (66.1) | 3 (12.5) | 21 (87.5) | 65 (25.5) | 190 (74.5) | |||
| Relationship to past initiates | |||||||||
| Family member/intimate partner | 0 (0) | 1 (100) | 0.01 | 0 (0) | 10 (100) | 0.36 | 7 (8.2) | 78 (91.8) | 0.06 |
| Friend | 15 (26.8) | 41 (73.2) | 9 (19.2) | 38 (80.9) | 87 (18.6) | 381 (81.4) | |||
| Other | 7 (77.8) | 2 (22.2) | 0 (0) | 6 (100) | 11 (21.6) | 40 (78.4) | |||
| More than one relationship | 2 (28.6) | 5 (71.4) | 5 (21.7) | 18 (78.3) | 19 (20.9) | 72 (79.1) | |||
| Reason for initiating | |||||||||
| Personal reason | 4 (26.7) | 11 (73.3) | 0.67 | 2 (40.0) | 3 (60.0) | 0.29 | 7 (15.2) | 39 (84.8) | 0.29 |
| Interpersonal reason | 14 (26.7) | 31 (68.9) | 4 (12.9) | 27 (87.1) | 98 (17.0) | 477 (83.0) | |||
| More than one reason | 5 (41.7) | 7 (58.3) | 8 (16.0) | 42 (84.0) | 17 (24.6) | 52 (75.4) | |||
Row percentages add up to 100.
PRIMER, Preventing Injecting by Modifying Existing Responses.